Market Overview

UPDATE: Citigroup Upgrades Acorda Therapeutics to Buy on Limited Downside, Catalysts

Share:
Related ACOR
8 Biggest Price Target Changes For Monday
Benzinga's Top Upgrades, Downgrades For March 13, 2017
Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers (Seeking Alpha)

Citigroup raised its rating on Acorda Therapeutics (NASDAQ: ACOR) from Neutral to Buy and raised its price target from $28 to $33.

Citigroup said, "We expect Ampyra to continue to grow fueled by modest market share gains and price increases. We project a 10% price increase in Q1:13 and 5% annually thereafter as there is still pricing power for the brand. This is overlooked by investors and should drive Ampyra's growth. We see limited downside to the stock as the stock is undervalued based on DCF esp. after its poor performance in 2012."

Acorda Therapeutics closed at $24.86 on Wednesday.

Latest Ratings for ACOR

DateFirmActionFromTo
Mar 2017Janney CapitalUpgradesNeutralBuy
Feb 2017Goldman SachsUpgradesSellNeutral
Dec 2016Janney CapitalInitiates Coverage OnNeutral

View More Analyst Ratings for ACOR
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ACOR)

View Comments and Join the Discussion!